Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 42, Issue 9 (Sep 2004)

Issues

The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen

Wolfgang Herrmann
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
/ Michael Stöckle
  • Department of Urology, University Hospital of Saarland, Homburg/Saar, Germany
/ Marga Sand-Hill
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
/ Ulrich Hübner
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
/ Markus Herrmann
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
/ Rima Obeid
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
/ Bernd Wullich
  • Department of Urology, University Hospital of Saarland, Homburg/Saar, Germany
/ Tillmann Loch
  • Department of Urology, University Hospital of Saarland, Homburg/Saar, Germany
/ Jürgen Geisel
  • Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, Homburg/Saar, Germany
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.211

Abstract

The aim of this study was to compare the diagnostic utility of complexed prostate-specific antigen (cPSA) with total PSA (tPSA) in screening for prostate cancer. Serum concentrations of tPSA and cPSA were measured in 4479 adult men during the prostate cancer screening program in the Saarland region (Germany). The percentage of men with c/tPSA ratio above the cut-off value of 0.75 increased with increasing tPSA intervals: tPSA 0–0.9 µg/l, 4.4%; 1.0–1.9 µg/l, 24.3%; 2.0–2.9 µg/l, 43.9%; 3.0–3.9 µg/l, 50.4%; and 4.0–20 µg/l, 60.2%. The commonly accepted tPSA cut-off value of 3.9 µg/l matched to the 93rd percentile of the overall population (corresponding cPSA value, 2.9 µg/l). A total of 202 men out of 313 with increased cPSA had increased c/tPSA ratio (cut-off ≥ 0.75) vs. 186 out of 312 men with increased tPSA. Thus, an additional 16 men at high risk for prostate cancer were selected only if cPSA was utilised as a first line parameter. Our data show that, compared to tPSA, cPSA measurement will always detect more high-risk patients, independent of the cut-off levels utilised for cPSA, tPSA and c/tPSA ratio. cPSA is more effective than tPSA in selecting subjects with an elevated c/tPSA ratio who are at high risk of prostate cancer. Thus, cPSA might be seen as the superior first-line parameter in screening for prostate cancer. Using lower cut-off values for tPSA or cPSA than the commonly accepted values seems reasonable for screening purposes.

Keywords: cancer of the prostate; complexed/free prostate-specific antigen ratio; complexed prostate-specific antigen; free prostate-specific antigen; prostate-specific antigen; screening

References

  • 1

    Crawford D, Waxman S. The history of prostate specific antigen. In: Brawer MK, editor. Prostate specific antigen. New York: Marcel Dekker Inc, 2001:1–8.

  • 2

    Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002; 59:2–8. [Crossref]

  • 3

    Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994; 102:S31–7.

  • 4

    Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37:1618–25.

  • 5

    Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60:4–9.

  • 6

    Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J Urol 1999; 162:293–306. [Crossref]

  • 7

    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8–31. [Crossref]

  • 8

    Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48:33–9. [Crossref]

  • 9

    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151:1283–90. [Web of Science]

  • 10

    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51:222–6.

  • 11

    Wu JT, Liu GH. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998; 12:32–40. [Crossref]

  • 12

    Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52:372–8. [Crossref]

  • 13

    Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46:55–62.

  • 14

    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. J Am Med Assoc 1997; 277:1452–55.

  • 15

    Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml? J Urol 2001; 165:1930–6.

  • 16

    Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl 1996; 7:64–9. [Crossref]

  • 17

    Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156–61.

  • 18

    Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002; 41:619–26. [Crossref]

  • 19

    Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998; 279:1542–7.

  • 20

    Oremek GM, Sapoutzis N, Eden F, Jonas D. Complexed PSA in routine diagnosis. Anticancer Res 2003; 23:975–7.

  • 21

    Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44:1216–23.

  • 22

    Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163:1476–80. [Crossref]

  • 23

    Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349:335–42.

  • 24

    Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, et al. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 2001; 39:57–64.

  • 25

    Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159:5–12.

  • 26

    Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49:19–27. [Crossref]

  • 27

    Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997; 43:1588–94.

  • 28

    Veltri RW, Miller MC, O’Dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002; 60:47–52. [Crossref]

  • 29

    Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. Urology 2002; 60:53–9. [Crossref]

  • 30

    Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, et al. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 2002; 60:24–30. [Crossref]

  • 31

    Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996; 48:81–7. [Crossref]

  • 32

    Woodrum D, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, et al. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48:33–9. [Crossref]

  • 33

    Kuriyama M, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, et al. Clinical evaluation of serum prostate-specific antigen-alpha 1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study. Int J Urol 1998; 5:48–54. [Crossref]

  • 34

    Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002; 60:31–5. [Crossref]

  • 35

    Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003; 170:1787–91.

About the article

Corresponding author: Prof. Dr. Wolfgang Herrmann, Department of Clinical Chemistry/Central Laboratory, University Hospital of Saarland, 66421 Homburg/Saar, Germany. Phone: +49-6841-1623070, Fax: +49-6841-1623109, E-mail:


Received: 2004-01-22

Accepted: 2004-07-12

Published Online: 2005-06-01

Published in Print: 2004-09-01



Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.211. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Hans-Joachim Luboldt, Joachim F. Schindler, and Herbert Rübben
EAU-EBU Update Series, 2007, Volume 5, Number 1, Page 38
[2]
Rainer Neumann
Jugoslovenska medicinska biohemija, 2006, Volume 25, Number 3, Page 235
[3]
Ralph Schiess, Bernd Wollscheid, and Ruedi Aebersold
Molecular Oncology, 2009, Volume 3, Number 1, Page 33
[4]
Klaus Jung, Michael Lein, Hermann Butz, Carsten Stephan, Stefan A. Loening, and Thomas Keller
The Journal of Urology, 2006, Volume 175, Number 4, Page 1275
[5]
Rainer Neumann
Jugoslovenska medicinska biohemija, 2006, Volume 25, Number 3, Page 235
[6]
J. Kellogg Parsons, Alan W. Partin, Bruce Trock, Debra J. Bruzek, Carol Cheli, and Lori J. Sokoll
BJU International, 2007, Volume 99, Number 4, Page 758
[7]
Michael Froehner, Oliver W. Hakenberg, Rainer Koch, Uta Schmidt, Axel Meye, and Manfred P. Wirth
Urologia Internationalis, 2006, Volume 76, Number 1, Page 27

Comments (0)

Please log in or register to comment.
Log in